Recent Updates
Recently added Catalysts

AD109 dose1- A

Phase 2

Obstructive Sleep Apnea | Small molecule | Respiratory |Apnimed, Inc.|Trials Updated: Dec 22, 2022

AD109 dose1- A development status

Highest phase Phase 2 (NCT04631107)
Registered trials 1 across 1 sponsor since Nov 2020

AD109 dose1- A target and mechanism

ModalitySmall molecule

Also known as AD109 75

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment32

FDA Designations

No designations recorded

AD109 dose1- A clinical trials

AD109 dose1- A · 1 trial · 1 indication

Phase 2 1
NCT04631107AD109 Dose Finding in Mild to Moderate OSAObstructive Sleep Apnea
COMPLETED32 Analytics
PHASE2COMPLETED
AD109 Dose Finding in Mild to Moderate OSA
Obstructive Sleep ApneaUnlock trial analytics

Study Endpoints

Primary Endpoints

Change in Hypoxic Burden (HB) Log Transformed - Log10HB[(%*Min)/h]
1 night (8 hours)

Change in Hypoxic Burden (HB) is calculated as the oxygen desaturation 'area under the curve' in association with individual apneas and hypopneas. Due to the known logarithmic distribution of HB, data are primarily expressed and analyzed as Log10HB 4%\[% min/h\]. Raw measurement of HB (%min/h) is defined as the sum of individual areas (%min) divided by total sleep time (h). Events with 4% or greater desaturations were included in the calculation of HB.

Change in Hypoxic Burden (HB) Raw Values - HB[(%*Min)/h]
1 night (8 hours)

Change in Hypoxic Burden (HB) is calculated as the oxygen desaturation 'area under the curve' in association with individual apneas and hypopneas. Raw measurement of HB (%min/h) is defined as the sum of individual areas (%min) divided by total sleep time (h). Events with 4% or greater desaturations were included in the calculation of HB.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Sequence ABCOTHERAD109 Dose 1- 75 mg (A), then AD109 Dose 2- 37.5 mg (B), then Placebo (C).
Sequence ACBOTHERAD109 Dose 1- 75 mg (A), then Placebo (C) then AD109 Dose 2- 37.5 mg (B)
Sequence BACOTHERAD109 Dose 2- 37.5 mg (B), then AD109 Dose 1- 75 mg (A), then Placebo (C)
Sequence BCAOTHERAD109 Dose 2- 37.5 mg (B), then Placebo (C), then AD109 Dose 1- 75 mg (A)
Sequence CABOTHERPlacebo (C), then AD109 Dose 1- 75 mg (A), then AD109 Dose 2- 37.5 mg (B)
Sequence CBAOTHERPlacebo (C), then AD109 Dose 2- 37.5 mg (B), then AD109 Dose 1- 75 mg (A)

Interventions

NameTypeDescription
AD109 dose1- ADRUGOral administration at bedtime
AD109 dose2- BDRUGOral administration at bedtime
Placebo- CDRUGOral administration at bedtime
Unlock Study Design Details

Eligibility Criteria

Age Range25 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: * AHI between 5 and 20 events/h * PGI-S equal to or higher than 1, or one or more of the following symptoms: * Snoring or nightime gasping/choking * Daytime sleepiness, fatigue or decreased concentration * Nonrefreshing sleep, sleep fragmentation (including from nocturia)...

Countries:United States
Unlock Eligibility Criteria